Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Holding PHAT?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.21Last Year’s EPS
-1.39Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 19, 2020
|% Change Since: -61.33%
|Next Earnings Date:Nov 25, 2019
Earnings Call Sentiment|Positive
Phathom Pharmaceuticals demonstrated strong commercial and financial performance in Q3 2024, marked by the successful launch and rapid adoption of VOQUEZNA, significant revenue growth, and financial stability. However, the company also faced increased SG&A expenses and reported a net loss, although these were anticipated investments tied to their strategic initiatives.Company Guidance
During the Phathom Pharmaceuticals third-quarter 2024 earnings call, significant guidance and metrics were provided to indicate the company's progress and future direction. Phathom reported net revenues of $16.4 million, reflecting a substantial over 120% quarter-over-quarter increase, attributed largely to the launch of VOQUEZNA for non-erosive GERD. With more than 143,000 prescriptions filled since launch, this represents a growth of nearly 140% since the last report. The commercial coverage for VOQUEZNA expanded to over 80% of U.S. commercial lives, now capturing an estimated 120 million people. Additionally, Phathom successfully raised $130 million in gross proceeds through an equity follow-on, enhancing its cash position to $335 million at the end of the quarter. The company continues to focus on maximizing VOQUEZNA's market potential, leveraging FDA approval for non-erosive GERD to increase its addressable market to approximately 22 million U.S. adults. The ongoing initiatives and robust financial position suggest Phathom is poised for continued growth, with an emphasis on increasing awareness and utilization of VOQUEZNA across both erosive and non-erosive GERD indications.Successful Commercial Launch of VOQUEZNA
VOQUEZNA's commercial launch is showing positive trends in prescription data, market sentiment, and patient access. FDA approval was secured for non-erosive GERD, expanding commercial access to over 80% of lives covered.
Significant Financial Achievements
Raised gross proceeds of $130 million in an equity follow-on, indicating capital market confidence. Net revenues of $16.4 million reported for Q3 2024, a sequential increase of over 120%.
VOQUEZNA Prescription Growth
More than 143,000 prescriptions filled since launch, marking a growth of nearly 140%. Q3 recorded approximately 69,000 filled prescriptions, almost doubling from Q2.
Positive Market Reception
VOQUEZNA has received multiple industry awards and increased media coverage. The GI community is excited about VOQUEZNA's potential to disrupt the PPI market.
Financial Stability
Ended Q3 with $335 million in cash, with additional debt facility available. Gross margin increased to 86%, reflecting a 440 basis point improvement over the last quarter.
---
PHAT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHAT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $18.00 | $18.50 | +2.78% |
| Aug 08, 2024 | $10.81 | $11.75 | +8.70% |
| May 09, 2024 | $10.10 | $10.09 | -0.10% |
| Mar 07, 2024 | $9.73 | $9.09 | -6.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Phathom Pharmaceuticals (PHAT) report earnings?
Phathom Pharmaceuticals (PHAT) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Phathom Pharmaceuticals (PHAT) earnings time?
Phathom Pharmaceuticals (PHAT) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAT EPS forecast?
PHAT EPS forecast for the fiscal quarter 2024 (Q4) is -1.21.
---